CDKN2B and glioblastoma: Among them, cyclin-dependent kinase 4 inhibitor B (CDKN2B) is correlated with SASP cytokine secretion in colorectal and liver cancers.121–123 Nevertheless, in glioblastoma patients, deletion of CDKN2A/B directly corresponds with worse overall survival rates.